A potential therapy targeting difficult-to-treat immune system disorders such as rheumatoid arthritis will progress to clinical trials next year after securing $20 million in Series A funding.
The KB312 antibody drug candidate was discovered by University of Queensland researchers in collaboration with the University of California San Francisco, Mater Research Institute-UQ and the Cooperative Research Centre (CRC) for Biomarker Translation.
